Octapharma intros Balfaxar

Octapharma USA is offering Balfaxar (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex). 

The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the Food and Drug Administration this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with need for urgent surgery or invasive procedures.

“The availability of Balfaxar brings a welcome new treatment option for medical providers around the country,” said Josh Goldstein, professor of Emergency Medicine at Harvard Medical School and Massachusetts General Hospital. “More than 2.4 million U.S. patients are prescribed warfarin to prevent blood clots from forming in patients who are at high risk. Unfortunately, the main side effect of warfarin is an increased risk of bleeding, which can complicate urgent surgery or invasive procedures. Clinical research has demonstrated that Balfaxar is extremely effective in restoring blood coagulation by replenishing the levels of clotting factors that are deficient in those patients on warfarin.”

[Read more: DSN webinar: Panelists weigh in on pharmacists' expanded role as providers]

Balfaxar is a non-activated 4F-PCC containing vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX and Factor X, as well as antithrombotic Proteins C and S.

“We are excited to announce the availability of Balfaxar and are committed to providing the medical community with a valuable life-saving therapy,” said Flemming Nielsen, president of Octapharma USA. "Octapharma has the production flexibility to ensure consistent supply for hospitals and medical providers now and in the future. We look forward to working with our critical care medicine partners to ensure patients receive the absolute best treatments available.”